When Johnson & Johnson announced the third phase of its Covid-19 vaccine clinical trial, US President Donald Trump said that four Covid-19 vaccine candidates are in the final stage.
Here is the status of the ongoing trials
Pfizer
The candidate vaccine being developed by Pfizer and its German partner BioNTech SE is considered the pioneer in the race. The President of the United States, Donald Trump, has indicated that this vaccine may become the first to obtain FDA approval.
Expected: The company has announced that by the end of October it will know if its vaccine works.
Modern
Moderna’s vaccine candidate, mRNA-1273, is nearing the finish line in its effort to enroll 30,000 people in an advanced-stage trial of a new coronavirus vaccine. The company plans to seek emergency clearance for high-risk groups if the vaccine proves effective.
Expected: Moderna aims to manufacture 20 million doses of vaccine by the end of 2020.
Oxford-Astrazeneca
The trial in the US is currently on hold because the US Food and Drug Administration has yet to give Astrazeneca the green light to resume its trial. On September 8, the pharmaceutical company, which is developing the vaccine in conjunction with the University of Oxford, announced that the disease was reported in two participants in the UK. After a brief hiatus, trials were resumed in the UK, Brazil and India.
Expected: The company aims for the vaccine to be available in early 2021.
Johnson and Johnson
Johnson & Johnson said Wednesday that it was entering the final stage of Phase 3 of its Covid-19 vaccine clinical trial following positive results in previous stages.
Expected: If the vaccine is shown to be safe and effective, Johnson & Johnson says it expects the first doses to be ready for emergency use authorization from the US Food and Drug Administration by early 2021.
.
